Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Advanced Metastatic NSCLC”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Not Yet RecruitingNCT07822542
What this trial is testing

A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Jiangsu Hansoh Pharmaceutical Co., Ltd. 448
Not applicableAvailableNCT06761976
What this trial is testing

Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation

Who this might be right for
Advanced Non-small Cell Lung CancerCancer
Bayer
Large-scale testing (Phase 3)Ended earlyNCT04746924
What this trial is testing

Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Who this might be right for
Non-small Cell Lung CancerNSCLC
BeiGene 669
Large-scale testing (Phase 3)UnknownNCT06110663
What this trial is testing

HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

Who this might be right for
Non-Small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 314
Large-scale testing (Phase 3)Active Not RecruitingNCT05690945
What this trial is testing

QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer
Qilu Pharmaceutical Co., Ltd. 606
Testing effectiveness (Phase 2)Looking for participantsNCT07012031
What this trial is testing

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

Who this might be right for
Locally Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8+1 more
National Cancer Institute (NCI) 37
Testing effectiveness (Phase 2)Study completedNCT01580735
What this trial is testing

ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer

Who this might be right for
Non-small-cell Lung Cancer
Kyowa Kirin Co., Ltd. 40
Testing effectiveness (Phase 2)Ended earlyNCT03149549
What this trial is testing

PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors

Who this might be right for
Solid Tumor, AdultBreast CancerNon Small Cell Lung Cancer+2 more
CytomX Therapeutics 99
Testing effectiveness (Phase 2)Active Not RecruitingNCT05565378
What this trial is testing

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Who this might be right for
Lung Cancer, Non-Small Cell
GlaxoSmithKline 351
Large-scale testing (Phase 3)Not Yet RecruitingNCT07633873
What this trial is testing

SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04）

Who this might be right for
Non-Small Cell Lung Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd. 500
Testing effectiveness (Phase 2)Looking for participantsNCT06616766
What this trial is testing

A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)Solid Tumor
Yuhan Corporation 201
Testing effectiveness (Phase 2)Study completedNCT01561456
What this trial is testing

Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung

Who this might be right for
Non-small-cell Lung CancerSquamous Cell CarcinomaAdenocarcinoma of the Lung
Axelar AB 100
Large-scale testing (Phase 3)Study completedNCT03802240
What this trial is testing

Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd. 492
Early research (Phase 1)Looking for participantsNCT07130916
What this trial is testing

Aumolertinib in European Participants With Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 20
Large-scale testing (Phase 3)Active Not RecruitingNCT05870319
What this trial is testing

A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients

Who this might be right for
Non-small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 376
Large-scale testing (Phase 3)Looking for participantsNCT06899126
What this trial is testing

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Daiichi Sankyo 686
Testing effectiveness (Phase 2)UnknownNCT05007938
What this trial is testing

Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd. 30
Testing effectiveness (Phase 2)Ended earlyNCT04971187
What this trial is testing

Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer

Who this might be right for
Locally Advanced Lung Non-Squamous Non-Small Cell CarcinomaMetastatic Lung Non-Squamous Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8+7 more
M.D. Anderson Cancer Center 3
Large-scale testing (Phase 3)Looking for participantsNCT06452277
What this trial is testing

Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Who this might be right for
Advanced Non-small Cell Lung Cancer, HER2 Mutation
Bayer 555
Testing effectiveness (Phase 2)Ended earlyNCT03330405
What this trial is testing

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Who this might be right for
Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
Pfizer 223
Next Page